CervoMed (CRVO) - 2024 Q4 - Annual Results

Exhibit 99.1 CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates -Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial's primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities- -Awarded 2024 Prix Galien USA Award as "Best Startup" by the Galien Foundation- Boston – March 17, 202 ...